Tag
Two phase 3 trials establish remibrutinib, a BTK inhibitor, as more effective and better tolerated than teriflunomide in relapsing multiple sclerosis, supporting its potential as a new oral treatment.
This article reviews evidence supporting OCT measurements of retinal layers as biomarkers for predicting multiple sclerosis progression and highlights the need for further research to enhance clinical application.
A Swedish cohort study reveals increased risk of inflammatory bowel disease in relapsing-remitting multiple sclerosis patients treated with rituximab compared to other therapies and the general population, underscoring the need for gastroin
This review synthesizes evidence comparing brain atrophy patterns in MS, MOGAD, and AQP4+ NMOSD, highlighting MOGAD’s atrophy association with inflammatory activity and lesion dynamics, emphasizing distinct pathogenic mechanisms and c
Continuous ocrelizumab treatment over 10 years in relapsing MS significantly delays disability progression, reduces relapse rates, and maintains a favorable safety profile, underscoring the clinical benefit of early high-efficacy therapy.
This study clarifies that cervical cord atrophy in MS is partly disease-specific beyond aging effects, with distinct patterns linked to age and disease onset, correlating with disability and neurodegeneration markers.
The LIMS study demonstrates sustained, modest improvements in MS-related functioning and dietary behavior up to 24 months following a digital multimodal lifestyle intervention, supporting lifestyle interventions as complementary to MS manag
This article reviews the development and validation of patient-reported outcome measures as interim endpoints in multi-arm multistage trials for progressive multiple sclerosis, highlighting their potential to accelerate therapeutic developm
Paramagnetic rim lesions detected via MRI are associated with increased risk of disability progression independent of relapse activity and accelerated brain atrophy in multiple sclerosis, highlighting their role as prognostic biomarkers for
Serum neurofilament light chain (sNfL) z-score dynamics enhance monitoring of treatment response in relapsing multiple sclerosis (RMS), providing complementary predictive value for disease activity beyond conventional clinical and MRI asses
Serum GFAP elevation predicts progression independent of relapse in MS; therapy-induced GFAP reduction associates with decreased progression risk, supporting GFAP as a biomarker for progression risk stratification and treatment monitoring.
A large US inpatient analysis found similar in-hospital mortality and complication rates after cardiovascular surgery in patients with and without multiple sclerosis, but patients with MS were less often discharged routinely home.
A large Sweden-France analysis suggests rising MS prevalence is mainly survival-driven, increasing MND prevalence reflects growing incidence, and PD prevalence rises modestly through mixed demographic and survival effects.
A new cohort study suggests ultra-widefield fluorescein angiography frequently detects persistent peripheral leakage in clinically inactive demyelinating disease-associated uveitis, highlighting a potential gap between examination-based rem
A large Ontario population study found that people with multiple sclerosis received palliative care at rates similar to other decedents, yet rural inequities and frequent hospital death persisted, highlighting the need for earlier neuropall
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
A new study reveals that neurologists receiving $1,000 or more from drug manufacturers were over 4 times more likely to prescribe expensive brand-name MS medications when generics were available, driving up costs for patients and the health
A retrospective study reveals that 24% of patients meeting the latest MS criteria following optic neuritis actually have MOGAD or NMOSD, emphasizing the need for antibody testing to prevent misdiagnosis.
A multicenter study reveals that nearly one-quarter of patients meeting the newest multiple sclerosis criteria for optic neuritis actually have MOGAD or NMOSD, emphasizing the critical role of antibody screening and detailed orbital MRI in
A large-scale multicenter study reveals that persistent high-level Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers serve as a highly specific biomarker, effectively distinguishing Multiple Sclerosis from other neuroinflammat
